| Literature DB >> 35740377 |
Hideki Takakura1,2,3, Toshimasa Nakao1, Takumi Narita1, Mano Horinaka1,2, Yukako Nakao-Ise1, Tetsushi Yamamoto4, Yosuke Iizumi1, Motoki Watanabe1, Yoshihiro Sowa1, Keisuke Oda3, Nobuhiro Mori3, Toshiyuki Sakai1,2, Michihiro Mutoh1.
Abstract
Edible plant-derived nanovesicles have been explored as effective materials for preventing colorectal cancer (CRC) incidence, dependent on gene status, as a K-Ras-activating mutation via the macropinocytosis pathway. Approximately 70% of CRC harbors the p53 mutation, which is strongly associated with a poor prognosis for CRC. However, it has not been revealed whether p53 inactivation activates the macropinocytosis pathway or not. In this study, we investigated parental cells, wild-type or null for p53 treated with Citrus limon L.-derived nanovesicles, as potential materials for CRC prevention. Using ultracentrifugation, we obtained C. limon L.-derived nanovesicles, the diameters of which were approximately 100 nm, similar to that of the exosomes derived from mammalian cells. C. limon L.-derived nanovesicles showed inhibitory effects on cell growth in not p53-wild, but also in p53-inactivated CRC cells. Furthermore, we revealed that the macropinocytosis pathway is activated by p53 inactivation and C. limon L.-derived nanovesicles were up taken via the macropinocytosis pathway. Notably, although C. limon L.-derived nanovesicles contained citrate, the inhibitory effects of citrate were not dependent on the p53 status. We thus provide a novel mechanism for the growth inhibition of C. limon L.-derived nanovesicles via macropinocytosis and expect to develop a functional food product containing them for preventing p53-inactivation CRC incidence.Entities:
Keywords: colorectal cancer; colorectal cancer prevention; edible plant; macropinocytosis; nanovesicles; p53
Year: 2022 PMID: 35740377 PMCID: PMC9219868 DOI: 10.3390/biomedicines10061352
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Citrus limon L.-derived nanovesicle concentration and components.
| Particle Concentration | Protein Concentration | Citrate Concentration |
|---|---|---|
| 3.38 × 1011 particles/mL | 625 μg/mL | 0.111 nM |
3.38 × 1011: the total number of digits is 12, and the first three digits are “338”.
Figure 1Analysis of the diameter and concentration for Citrus limon L.-derived nanovesicles using TEM and NTA. (A) Photograph of C. limon L. before obtaining juice (lemon in the back of the photo) and after obtaining juice by squeezing (lemon in front of the photo). (B) Representative photograph of nanovesicles obtained at 50,000× magnification using transmission electron microscopy. Scale bar, 100 nm. (C) Size distribution of nanovesicles. Size distributions were determined by the nanoparticle tracking analysis.
Figure 2p53 status affects the inhibition of cell growth through Citrus limon L.-derived nanovesicle treatment. (A) HCT116 WT, HCT-15, and SW480 cells were treated with the indicated concentrations of C. limon L.-derived nanovesicles for 72 h. (B,C) HCT116 WT or HCT116 p53 (-/-) cells were treated with the indicated concentrations of C. limon L.-derived nanovesicles for 24, 48, and 72 h. Cell growth was measured using a Cell Counting Kit-8 assay. Data are means ± standard error measurement; n = 3; * p < 0.05, relative to HCT116 WT. p values were calculated using Dunnett’s multiple comparisons test and Sidak’s multiple comparisons test.
Figure 3Uptake of Citrus limon L.-derived nanovesicles via macropinocytosis in colorectal cancer cells. HCT116 WT, HCT116 p53 (-/-), and SW480 cells were treated with labeled nanovesicles and/or FITC-dextran (70 kDa, macropinocytosis marker) at 37 °C. (A) After 24 h, the nuclei were stained with Hoechst 33342. These images were obtained using a fluorescence microscope. Scale bar, 20 μm. (B,C) After 6 h, relative cellular uptake analysis of labeled nanovesicles or FITC-dextran on these cells through flow cytometry. Data are means ± standard error measurement; n = 3; * p < 0.05, relative to HCT116 WT. p values are calculated using an unpaired t test.
Figure 4Citrate shows p53-independent inhibitory effects on HCT116 cells. (A) HCT116 WT or HCT116 p53 (-/-) cells were treated with the indicated concentrations of citrate for 72 h. Cell growth was measured using a Cell Counting Kit-8 assay. (B) HCT116 p53 (-/-) cells were treated with the indicated concentrations of Citrus limon L.-derived nanovesicles for 6 h. Intracellular pH was measured using a BCECF-AM assay. Data are means ± standard error measurement; n = 3; * p < 0.05, relative to the PBS (-) control. p values were calculated using Dunnett’s multiple comparisons test and Sidak’s multiple comparisons test.